Promising therapeutic profile observed encouraged ongoing trials to further investigate the clinical potential of olaparib in IDH1/2-mutant GBM [144] as well as tumour protein P53 (TP53) mutant GBM (NCT05432518). Here, IDH1 is linked to glioblastoma.